| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/02/2005 | CN1187086C Hybrid with interferon alpha and immunoglobulin Fc linked through non-immunogenic peptide |
| 02/02/2005 | CN1187069C Method for extracting coxtex mouten total glucoside for treating hepatitis |
| 02/02/2005 | CN1187065C Ointment for treating dermatopathy and preparing process thereof |
| 02/02/2005 | CN1187064C Medicine for treating epidemic hemorrhagic fever |
| 02/02/2005 | CN1187057C Trivalent cerium carried rectorite anti-inflammatory and bacteriostatic medicine and preparation process thereof |
| 02/02/2005 | CN1187052C Sustained release microsphere containing stavudine |
| 02/02/2005 | CN1186983C Technique for detoxicating white spot syndrome virus of prawn |
| 02/01/2005 | US6849737 Synthesis and purification of valacyclovir |
| 02/01/2005 | US6849736 Crystalline forms of valacyclovir hydrochloride |
| 02/01/2005 | US6849713 Topisomerase inhibitor |
| 02/01/2005 | US6849709 Aerothricin derivatives |
| 02/01/2005 | US6849660 Antimicrobial biaryl compounds |
| 02/01/2005 | US6849653 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 02/01/2005 | US6849643 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 02/01/2005 | US6849635 Sulfonamides |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849617 Administering Tissue factor pathway inhibitors for prophylaxis of thrombosis and cardiovascular disorders; anticoagulants |
| 02/01/2005 | US6849612 Oligonucleotide modulation of cell adhesion |
| 02/01/2005 | US6849608 Macrolide antibiotics |
| 02/01/2005 | US6849598 A microbiocides, bactericides, fungicides, comprising a surfactant poloxamer, optionally with EDTA, for treating bacterial infections |
| 02/01/2005 | US6849596 Regulatory/unfolding peptides of ezrin |
| 02/01/2005 | US6849593 Bifidogenic peptides |
| 02/01/2005 | US6849452 Bringing an enriched population of resting NK cells into contact with mature or triggered dendritic cells in vitro or ex vivo, under conditions allowing activation of such resting NK cells by mature or triggered cells |
| 02/01/2005 | US6849451 Hybrid cells |
| 02/01/2005 | US6849446 Genetic engineering |
| 02/01/2005 | US6849261 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 02/01/2005 | US6849058 Treating rheumatoid arthritis by administering a photoactive compound such as a porphyrin systemically, directly to an affected joint or extracorporally to blood and irradiating to effect activation; returning blood to body |
| 02/01/2005 | CA2419729C Crystal form ii of clarithromycin |
| 02/01/2005 | CA2183976C Process for making an epoxide |
| 02/01/2005 | CA2094261C Polypeptide of a growth factor receptor family, application in the diagnosis and treatment of myeloproliferative diseases |
| 01/27/2005 | WO2005007686A1 Rna binding peptide |
| 01/27/2005 | WO2005007685A1 Cylic polypeptides that can combine with rnaiii activating protein secreted by staphylococcus aureus and their medical use |
| 01/27/2005 | WO2005007684A1 Small molecule peptide to bind trap and their medicinal use |
| 01/27/2005 | WO2005007683A1 Antigen epitopes of the regulatory protein of virulence factor in staphylococcus aureus and their mimotopes and use |
| 01/27/2005 | WO2005007681A2 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/27/2005 | WO2005007669A1 Novel fusidic acid derivatives |
| 01/27/2005 | WO2005007656A1 Spiro compounds and methods for the modulation of chemokine receptor activity |
| 01/27/2005 | WO2005007640A1 Preventive or therapeutic composition for viral infectious disease |
| 01/27/2005 | WO2005007629A1 Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity |
| 01/27/2005 | WO2005007192A2 Cytoprotection through the use of hif hydroxylase inhibitors |
| 01/27/2005 | WO2005007187A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 01/27/2005 | WO2005007178A1 Treatment of malodour |
| 01/27/2005 | WO2005007162A1 Compounds augmenting the activity of antibacterial agents |
| 01/27/2005 | WO2005007153A1 A composition of amino acid-iodine complex and methods for preparing and application |
| 01/27/2005 | WO2005007141A2 Ubiquitin ligase inhibitors and methods related thereto |
| 01/27/2005 | WO2005007070A2 Stable pharmaceutical composition |
| 01/27/2005 | WO2005007069A2 Soft gel formulations for saquinavir |
| 01/27/2005 | WO2004087647A3 4-substituted quinolein derivatives with antimicrobial activity |
| 01/27/2005 | WO2003090687A3 Using heat shock proteins to increase immune response |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2002087554B1 Ef-tu binding agent as antibacterial agent |
| 01/27/2005 | US20050020823 23-O-substituted 5-O-mycaminosyltylonide derivatives |
| 01/27/2005 | US20050020813 Streptococcus pneumoniae proteins and nucleic acids |
| 01/27/2005 | US20050020653 Imidazolyl or benzimidazolyl derivatives of triazole compounds substituted at 2 position; anti-fungal agent with broad spectrum activity useful in the treatment of fungal infections in animals, including humans and as agricultural fungicides |
| 01/27/2005 | US20050020624 Dihydroindole and tetrahydroquinoline derivatives |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020572 Therapy for bacteria infections |
| 01/27/2005 | US20050020566 Novel carbapenem compounds |
| 01/27/2005 | US20050020545 Substituted tetracycline compounds as antifungal agents |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020517 Treatment of HIV infection through combined administration of tipranavir and capravirine |
| 01/27/2005 | US20050020514 From fermentation of Streptomyces; bactericides |
| 01/27/2005 | US20050020511 Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020503 Hepatitis C inhibitor compounds |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019894 used to treat probiotic infectious diarrhea caused by pathogenic microorganisms, gastroenteritis, inflammatory intestinal disease, neurological intestinitis syndrome, overgrowth of small intestinal microorganisms and intestinal feeding diarrhea. |
| 01/27/2005 | US20050019892 Screening process for antibacterial agents |
| 01/27/2005 | US20050019754 Peptides of given sequence with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/27/2005 | US20050019751 Contacting human scavenger receptor class B type I with polypeptide and measuring ability of test compound to inhibit binding; used in treatment and prophylaxis |
| 01/27/2005 | US20050019433 Negatively charged polysaccharide derivable from aloe vera |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019403 comprising immediate release, sustained release and delayed release dosage forms, with each dosage forms having a different release profile, wherein each reaches a maximum concentration at different times |
| 01/27/2005 | US20050019402 Antibiotic product, use and formulation thereof |
| 01/27/2005 | US20050019401 comprising immediate release, sustained release and delayed release dosage forms, with each dosage forms having a different release profile, wherein each reaches a maximum concentration at different times |
| 01/27/2005 | US20050019396 formed by mixing metal salts with the aqueous solutions, then mixing with bases to increase the pH of the aqueous solution and forming suspensions of antibiotic metal complex, and drying the suspension by dry granulation |
| 01/27/2005 | US20050019391 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/27/2005 | US20050019389 Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
| 01/27/2005 | US20050019349 Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| 01/27/2005 | US20050019347 Dna sequences and coding for hepatitis virus antigen |
| 01/27/2005 | US20050019344 Antigens; vaccines; isolated peptide |
| 01/27/2005 | US20050019337 Immunization method against Neisseria meningitidis serogroups A and C |
| 01/27/2005 | US20050019335 Attenuated mutant Salmonella bacteria containing deactivated gene used as vaccine |
| 01/27/2005 | US20050019333 Glycosylated specificity exchangers |
| 01/27/2005 | US20050019274 Biofilm removing agent for removing a biofilm |
| 01/27/2005 | CA2573951A1 Spiro compounds and methods for the modulation of chemokine receptor activity |
| 01/27/2005 | CA2532725A1 Novel fusidic acid derivatives |
| 01/27/2005 | CA2532664A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/27/2005 | CA2522508A1 Antisense antiviral agent and method for treating ssrna viral infection |
| 01/26/2005 | EP1500698A1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| 01/26/2005 | EP1500643A1 Benzamide derivatives |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500400A1 Drug containing antibody composition |
| 01/26/2005 | EP1500389A1 Biofilm removing agent |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499726A1 Chimeric camp factors for vaccination against streptococcus infection |
| 01/26/2005 | EP1499633A2 Hagfish cathelin-associated antimicrobial peptides and genes |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499622A1 Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors |